UEG's content platform for gastroenterology education bringing recordings, courses, guidelines, and more together in one place.

UEG Week Berlin 2025 Recordings Gut Guide online What's new on Gutflix

Trending on Gutflix

Rate for better recommendations!

Your feedback helps us show you more of what you like and less of what you dislike!

More of this!

We will show you more similar content.

Not for me!

We won't suggest this again.

Bookmark!

Save this content for later!

New to myUEG? Create an account! Log In with myUEG account

UEG Presentation

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

THE IMPACT OF FODMAP RESTRICTION AND REINTRODUCTION ON THE GUT MICROBIOTA OF PATIENTS WITH IRRITABLE BOWEL SYNDROME AND ITS ASSOCIATION WITH CLINICAL RESPONSE

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

THE IMPACT OF FODMAP RESTRICTION AND REINTRODUCTION ON THE GUT MICROBIOTA OF PATIENTS WITH IRRITABLE BOWEL SYNDROME AND ITS ASSOCIATION WITH CLINICAL RESPONSE

Arnau Vich Vila 1, Karen Van den Houte 2, Karen Routhiaux 2, Florencia Carbone 3, Muriel Derrien 1, Jan Tack 4, Jeroen Raes 1

Affiliations

1 Vlaams Instituut voor Biotechnologie, Leuven, Belgium

2 KU Leuven, Leuven, Belgium

3 University of Leuven, Leuven, Belgium

4 University of Leuven, University Hospital Gasthuisberg, Leuven, Belgium

Summary

AI Generated

Analysis of over 1,700 faecal samples from 463 IBS patients shows that baseline dysbiotic microbiota predicts poorer response to FODMAP restriction, and individual FODMAPs exert distinct prebiotic effects on gut bacteria independent of symptom tolerance.

Participants with dysbiotic microbiota at baseline were less likely to respond to FODMAP dietary restriction (p=0.01) and showed higher fecal calprotectin, secretory IgA, and eosinophil-derived neurotoxin, suggesting immune activation (p<0.05).
FODMAP restriction decreased Bifidobacterium abundance in both cohorts (FDR<0.01), with a dose-dependent effect: the less restrictive DOMINO diet caused milder depletion than strict restriction, independent of response and IBS subtype.
Reintroduction of galacto-oligosaccharides and fructans restored Bifidobacterium levels, while polyols increased Anaerostipes abundance, regardless of participants' tolerance (FDR<0.05).
Total bacterial biomass did not change during restriction or reintroduction, and 25 significant associations were found between individual FODMAPs and gut bacteria.
Participants intolerant to sorbitol showed increased Alistipes upon exposure (p<0.05, FDR>0.05), suggesting FODMAP-specific microbial dynamics, though these did not reach significance after multiple testing correction at the current sample size.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Abstract

Introduction

The pathophysiological mechanism involved in irritable bowel syndrome (IBS) is thought to be multifactorial, involving the gut-brain axis and the immune system. Despite this complexity, dietary restriction of fermentable oligo-, dis-, mono- saccharides, and polyols (FODMAPs) has become the first line of treatment, improving symptoms in up to 80% of patients (1). FODMAPs are poorly absorbed in the small intestine and serve as a substrate for the colonic microbiota, which has been proposed as a key mediator of FODMAP tolerance and symptom development. Considering that both the gut microbiota and the (in)tolerance to individual FODMAPs are highly personalised (2), there is a growing need to understand the host-microbiota interactions underlying individual responses to FODMAP restriction and intake. This personalised interplay may be key to more targeted dietary interventions for IBS.

Aims & Methods

We aimed to disentangle the role of the gut microbiota in FODMAP tolerance by exploring microbial dynamics upon restriction and reintroducing individual FODMAPs. To this end, we performed 16S rRNA gene sequencing of over 1,700 faecal samples from 463 IBS patients participating in two clinical trials: a) The DOMINO trial (3), where primary-care patients underwent a FODMAP-lowering diet and b) A cohort of 117 tertiary-care patients underwent a strict FODMAP-restriction followed by a blinded re-introduction of 6 FODMAPs powders (2). Response to the diet was defined as a reduction of at least 50 points on the IBS symptom severity scale. Linear and logistic mixed models were used to assess the relation between the microbiome, response to dietary intervention, host genetics and 32 blood and faecal parameters.

Results

Participants with dysbiotic microbiota at baseline were shown to be less likely to respond to the dietary restriction (p-value=0.01). These participants also showed higher levels of fecal calprotectin, secretory IgA and eosinophil-derived neurotoxin, suggesting immune activation in this subgroup of IBS patients (p-value<0.05). In both cohorts, limiting FODMAP intake was associated with decreased Bifidobacterium abundance (FDR<0.01). Moreover, a dose-dependent effect was observed as depletion was less severe in the FODMAP-lowering DOMINO diet. This effect was independent of response and IBS subtype. Furthermore, total bacterial biomass did not change during the restriction or the reintroduction period. However, we found 25 significant associations between individual FODMAPs and gut bacteria. The reintroduction of galacto-oligosaccharides and fructans restored the levels of Bifidobacterium, while polyols increased the abundance of Anaerostipes, regardless of participants’ tolerance (FDR<0.05). In addition, we observed distinct dynamics in the gut microbiota associated with the tolerance of specific FODMAPs, although they did not reach significance after multiple testing corrections at the current sample size. For example, participants intolerant to sorbitol showed an increase in Alistipes upon exposure to this compound (p-value<0.05, FDR>0.05).

Conclusion

Our results suggest that microbiota composition at baseline influences the clinical response to FODMAP restriction. A low-FODMAP diet does not induce drastic changes in the microbiome composition, although we confirmed the negative impact of dietary restriction on the abundance of Bifidobacterium. However, the less restrictive DOMINO diet results in a milder depletion, suggesting that moderate FODMAP reduction may better preserve beneficial microbiota while still offering symptom relief. Finally, we found evidence for a link between microbial dynamics and FODMAP tolerance, although this needs to be confirmed in larger cohorts.

References

(1) Staudacher HM, Whelan K The low FODMAP diet: recent advances in understanding its mechanisms and efficacy in IBS Gut 2017;66:1517-1527.
(2) Van den Houte K, Colomier E, Routhiaux K, Mariën Z, Schol J, Van den Bergh J, Vanderstappen J, Pauwels N, Joos A, Arts J, Caenepeel P, De Clerck F, Matthys C, Meulemans A, Jones M, Vanuytsel T, Carbone F, Tack J. Efficacy and Findings of a Blinded Randomized Reintroduction Phase for the Low FODMAP Diet in Irritable Bowel Syndrome. Gastroenterology. 2024
(3) Carbone F, Van den Houte K, Besard L DOMINO Study Collaborators, et al Diet or medication in primary care patients with IBS: the DOMINO study - a randomised trial supported by the Belgian Health Care Knowledge Centre (KCE Trials Programme) and the Rome Foundation Research Institute Gut 2022;71:2226-2232.

Disclosure

JT has given Scientific advice to AlfaWassermann, Allergan, Christian Hansen, Danone, Grünenthal, Ironwood, Janssen, Kiowa Kirin, Menarini, Mylan, Neutec, Novartis, Noventure, Nutricia, Shionogi, Shire, Takeda, Theravance, Tramedico, Truvion, Tsumura, Zealand and Zeria pharmaceuticals, has received research support from Shire, Sofar and Tsumura, and has served on the Speaker bureau for Abbott, Allergan, AstraZeneca, Janssen, Kyowa Kirin, Menarini, Mylan, Novartis, Shire, Takeda, Truvion and Zeria. Funding was provided by a Methusalem grant from Leuven University to JT This study was supported by a research grant from the Belgian Health Care Knowledge Centre (KCE).

Event

UEG Week Berlin 2025

Topics

Gut Microbiota Neurogastroenterology & Motility Small Intestine & Nutrition Colorectal

Submission format

Abstract

Session

Lower GI motility II

Citation

United European Gastroenterology Journal 2025; 13 (Supplement 8)

Published

2025

More Like This:

What treatment can we offer?

Jordi Serra

What the gastroenterologist can offer

Giovanni Sarnelli

DUPILUMAB IMPROVES HISTOPATHOLOGIC DISEASE ACTIVITY OVER 52 WEEKS IN CHILDREN WITH EOSINOPHILIC ESOPHAGITIS: FINDINGS FROM THE PHASE 3 EOE KIDS STUDY

Amr Radwan

WESTERNIZED DIETS EXACERBATE TUMORIGENESIS BY EXPANDING H2S-PRODUCING DESULFOVIBRIO IN MURINE MODELS OF ATF6-DRIVEN COLON CANCER

Miriam von Stern-Gwiazdowski

$How to manage refractory reflux$

How to manage refractory reflux

Jordi Serra

TARGETED VERSUS POPULATION-BASED SCREENING AS A PRIMARY PREVENTIVE APPROACH TOWARDS GASTRIC CANCER: INTERIM RESULTS OF THE IRISH EXPERIENCE

Colm O'Morain

UEG Presentation

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

What treatment can we offer?

Jordi Serra 1

Affiliations

1 University Hospital Vall d'Hebron, Barcelona, Spain

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

Abstract

Event

UEG Week Berlin 2025

Topics

Primary Care

Session

Bloating

Citation

United European Gastroenterology Journal 2025; 13 (Supplement 8)

Published

2025

More Like This:

What treatment can we offer?

Jordi Serra

What the gastroenterologist can offer

Giovanni Sarnelli

DUPILUMAB IMPROVES HISTOPATHOLOGIC DISEASE ACTIVITY OVER 52 WEEKS IN CHILDREN WITH EOSINOPHILIC ESOPHAGITIS: FINDINGS FROM THE PHASE 3 EOE KIDS STUDY

Amr Radwan

WESTERNIZED DIETS EXACERBATE TUMORIGENESIS BY EXPANDING H2S-PRODUCING DESULFOVIBRIO IN MURINE MODELS OF ATF6-DRIVEN COLON CANCER

Miriam von Stern-Gwiazdowski

$How to manage refractory reflux$

How to manage refractory reflux

Jordi Serra

TARGETED VERSUS POPULATION-BASED SCREENING AS A PRIMARY PREVENTIVE APPROACH TOWARDS GASTRIC CANCER: INTERIM RESULTS OF THE IRISH EXPERIENCE

Colm O'Morain

UEG Presentation

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

What the gastroenterologist can offer

Giovanni Sarnelli 1

Affiliations

1 University of Naples 'Federico II', Pozzuoli NA, Italy

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

Abstract

Event

UEG Week Berlin 2025

Topics

Neurogastroenterology & Motility Primary Care

Session

Therapy update: Dyspepsia

Citation

United European Gastroenterology Journal 2025; 13 (Supplement 8)

Published

2025

More Like This:

What treatment can we offer?

Jordi Serra

What the gastroenterologist can offer

Giovanni Sarnelli

DUPILUMAB IMPROVES HISTOPATHOLOGIC DISEASE ACTIVITY OVER 52 WEEKS IN CHILDREN WITH EOSINOPHILIC ESOPHAGITIS: FINDINGS FROM THE PHASE 3 EOE KIDS STUDY

Amr Radwan

WESTERNIZED DIETS EXACERBATE TUMORIGENESIS BY EXPANDING H2S-PRODUCING DESULFOVIBRIO IN MURINE MODELS OF ATF6-DRIVEN COLON CANCER

Miriam von Stern-Gwiazdowski

$How to manage refractory reflux$

How to manage refractory reflux

Jordi Serra

TARGETED VERSUS POPULATION-BASED SCREENING AS A PRIMARY PREVENTIVE APPROACH TOWARDS GASTRIC CANCER: INTERIM RESULTS OF THE IRISH EXPERIENCE

Colm O'Morain

UEG Presentation

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

DUPILUMAB IMPROVES HISTOPATHOLOGIC DISEASE ACTIVITY OVER 52 WEEKS IN CHILDREN WITH EOSINOPHILIC ESOPHAGITIS: FINDINGS FROM THE PHASE 3 EOE KIDS STUDY

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

DUPILUMAB IMPROVES HISTOPATHOLOGIC DISEASE ACTIVITY OVER 52 WEEKS IN CHILDREN WITH EOSINOPHILIC ESOPHAGITIS: FINDINGS FROM THE PHASE 3 EOE KIDS STUDY

Margaret H. Collins 1, Diana Lerner 2, Robbie Pesek 3, Noam Zevit 4, Changming Xia 5, Sherif Zaghloul 6, Bram Raphael 5, James T. Angello 6, Amr Radwan 5

Affiliations

1 Cincinnati Children’s Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, United States

2 Medical College of Wisconsin, Milwaukee, United States

3 University of Arkansas for Medical Sciences and Arkansas Children’s Hospital, Little Rock, United States

4 Schneider Childrens Medical Center of Israel, Petach Tikva, Israel

5 Regeneron Pharmaceuticals Inc, Tarrytown, United States

6 Sanofi, Morristown, United States

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

Abstract

Introduction

Eosinophilic esophagitis (EoE) is a chronic, progressive, esophageal disease driven by type 2 inflammation.

Aims & Methods

The aim of this analysis was to determine the histopathologic effect of dupilumab on esophageal inflammation in patients aged 1–11 years with eosinophilic esophagitis (EoE) from the phase 3 EoE KIDS trial. In Part A, patients were randomized to receive weight-tiered dupilumab or placebo for 16 weeks. In Part B, all patients received weight-tiered dupilumab for 36 weeks. Biopsies from proximal, mid, and distal esophageal regions were analyzed. Peak eosinophil count (PEC) and EoE Histologic Scoring System (HSS) grade/stage scores were assessed at baseline, Week 16, and Week 52.

Results

At Week 16, dupilumab vs placebo treatment resulted in significantly greater improvements in PEC (least squares mean percent change -86.09% vs 20.98%, respectively; P<0.0001) and improvements from baseline were observed in EoE-HSS grade and stage total scores, and inflammatory and architectural sub-scores (Table). Improvements were maintained at Week 52 with continued dupilumab. For those who switched from placebo at Week 16, improvements were observed at Week 52. Improvements in individual component scores were also observed.

Table. Mean percent change from Part A baseline in EoE-HSS scores at Weeks 16 and 52.

	Week 16^a			Week 52
	Placebo (N=34)	Dupilumab (N=37)	LS mean difference	Placebo (N=18)	Dupilumab (N=37)
EoE-HSS grade
Total score	5.0%	-64.4%	-69.4****	-63.6%	-68.5%
Inflammatory sub-score	5.7%	-77.4%	-83.1****	-79.4%	-83.7%
Architectural sub-score	1.0%	-50.5%	-51.5****	-45.3%	-55.5%
EoE-HSS stage
Total score	5.8%	-62.3%	-68.1****	-58.2%	-63.5%
Inflammatory sub-score	7.9%	-96.3%	-104.3****	-89.6%	-96.6%
Architectural sub-score	9.0%	-41.0%	-50.0****	-32.4%	-51.0%

****P<0.0001.^aLS mean percent change.
EoE-HSS, Eosinophilic Esophagitis Histologic Scoring System; LS, least squares.

Conclusion

Dupilumab treatment improved a range of histopathologic aspects of EoE through 52 weeks versus placebo in children aged 1–11 years with EoE.

Disclosure

Collins MH: Arena, Pfizer, AstraZeneca, Calypso Biotech, EsoCap Biotech, GSK, Receptos, Celgene, Bristol Myers Squibb, Regeneron Pharmaceuticals Inc., Robarts Clinical Trials Inc. Alimentiv, Inc., Sanofi, Shire, a Takeda company – advisory board/consultancy fees.
Lerner D: Regeneron Pharmaceuticals Inc. – educational board fees.
Pesek RD: Regeneron Pharmaceuticals Inc. – advisory board/consultancy fees.
Zevit N: AstraZeneca, Rafa Inc., Regeneron Pharmaceuticals Inc., Sanofi, Takeda – advisory board/consultancy fees. Adare Pharmaceuticals, Dr. Falk Pharma – advisory board/consultancy fees. Dr. Falk Pharma, Rafa Inc., Regeneron Pharmaceuticals Inc., Sanofi – speaker fees. Rome Foundation – honoraria.
Xia C, Raphael BP, Radwan A: Regeneron Pharmaceuticals Inc. – employees and shareholders.
Zaghloul S, Angello JT: Sanofi – employees, may hold stock and/or stock options in the company.

Event

UEG Week Berlin 2025

Topics

Histopathology Mechanisms & Personalised Medicine Oesophagus

Submission format

Abstract

Session

EoE: From gene to clinic

Citation

United European Gastroenterology Journal 2025; 13 (Supplement 8)

Published

2025

More Like This:

What treatment can we offer?

Jordi Serra

What the gastroenterologist can offer

Giovanni Sarnelli

DUPILUMAB IMPROVES HISTOPATHOLOGIC DISEASE ACTIVITY OVER 52 WEEKS IN CHILDREN WITH EOSINOPHILIC ESOPHAGITIS: FINDINGS FROM THE PHASE 3 EOE KIDS STUDY

Amr Radwan

WESTERNIZED DIETS EXACERBATE TUMORIGENESIS BY EXPANDING H2S-PRODUCING DESULFOVIBRIO IN MURINE MODELS OF ATF6-DRIVEN COLON CANCER

Miriam von Stern-Gwiazdowski

$How to manage refractory reflux$

How to manage refractory reflux

Jordi Serra

TARGETED VERSUS POPULATION-BASED SCREENING AS A PRIMARY PREVENTIVE APPROACH TOWARDS GASTRIC CANCER: INTERIM RESULTS OF THE IRISH EXPERIENCE

Colm O'Morain

UEG Presentation

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

WESTERNIZED DIETS EXACERBATE TUMORIGENESIS BY EXPANDING H2S-PRODUCING DESULFOVIBRIO IN MURINE MODELS OF ATF6-DRIVEN COLON CANCER

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

WESTERNIZED DIETS EXACERBATE TUMORIGENESIS BY EXPANDING H2S-PRODUCING DESULFOVIBRIO IN MURINE MODELS OF ATF6-DRIVEN COLON CANCER

Isabel Keidel 1, Jagadrupa Sahoo 1, Miriam von Stern-Gwiazdowski 2, Hélène Omer 1, Tingting Zheng 1, Miriam Wimmer 2, Andreas Dunkel 2, Katja Steiger 3, Olivia Coleman 2, Melanie Schirmer 1, Dirk Haller 1

Affiliations

1 Technical University of Munich, Freising, Germany|||Technical University of Munich, Freising, Germany

2 Technical University of Munich, Freising, Germany

3 Technical University of Munich, München, Germany

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

Abstract

Introduction

The interplay of diet and the intestinal microbiome plays a key role in developing colorectal cancer (CRC), with westernization of diets, e.g., an increase in fat and sugar and a decrease in fiber content, being the main contributor. We recently demonstrated that the endoplasmic reticulum unfolded protein response (ER-UPR) effector activating transcription factor 6 (ATF6) is associated with early and late onset of CRC in patients. Furthermore, the overexpression of ATF6 observed in a subset of CRC patients is associated with the presence of certain gut bacteria. The specific expression of activated ATF6 (nATF6) in mouse intestinal epithelial cells (nATF6^IEC) induces spontaneous development of colonic tumors in a microbiota-dependent manner, highlighting the functional relevance of ATF6 as a novel oncogenic driver.

Aims & Methods

To elucidate the adverse role of dietary fat, sugar, and fiber in tumorigenesis, we exposed nATF6^IEC mice under SPF conditions to control (chow) and westernized diets for 7 weeks after weaning. Microbial and metabolite profiles were assessed through deep metagenomic sequencing and targeted/untargeted mass spectrometry (LC-MS) analysis. Microbiota transfer of diet-exposed mice into germ-free recipients was conducted to verify the microbiota-dependent transmissibility of tumor formation. Bismuth(II)subsalicylate (BSS) was used as a dietary additive to validate the impact of bacteria-produced H₂S on tumorigenesis.

Results

Westernized high lard (HL) diet, enriched in fat and sugar and depleted in fermentable fiber, increased tumor burden in biallelic nATF6^IEC mice. Unexpectedly, HL induced de novo tumorigenesis in otherwise tumor-free monoallelic nATF6^IEC mice. Surprisingly, modifying the HL diet by supplementing dietary fiber or lowering fat content failed to protect the HL-induced tumorigenic phenotype. Metabolite profiling clearly differentiated westernized from control diets and tumor bearing from control mice. Transferring microbiota from diet-exposed mice into germ-free nATF6^IEC mice was sufficient to trigger tumorigenesis. Metagenomic profiles of westernized diet-exposed mice identified an increased relative abundance of H₂S-producing Desulfovibrio species and genes related to dissimilatory sulfate reduction. Supplementing westernized diets with the H₂S-scavenger BSS resulted in a drastic change in microbial communities as well as the prevention of tumor formation in monoallelic nATF6^IECmice.

Conclusion

These results highlight the ability of westernized diets to enhance nATF6-related tumorigenesis while altering metabolite and microbial profiles. Westernized diets favor the growth of sulfate-reducing Desulfovibrionaceae, possibly resulting in increased H₂S production. H₂S scavenging significantly reduces diet-induced colonic tumor susceptibility, clearly demonstrating the impact of diet in shaping cancer-related microbiome alterations.

Event

UEG Week Berlin 2025

Topics

Digestive Oncology Gut Microbiota Immunology Mechanisms & Personalised Medicine Colorectal

Submission format

Abstract

Session

Oncobiome

Citation

United European Gastroenterology Journal 2025; 13 (Supplement 8)

Published

2025

More Like This:

What treatment can we offer?

Jordi Serra

What the gastroenterologist can offer

Giovanni Sarnelli

DUPILUMAB IMPROVES HISTOPATHOLOGIC DISEASE ACTIVITY OVER 52 WEEKS IN CHILDREN WITH EOSINOPHILIC ESOPHAGITIS: FINDINGS FROM THE PHASE 3 EOE KIDS STUDY

Amr Radwan

WESTERNIZED DIETS EXACERBATE TUMORIGENESIS BY EXPANDING H2S-PRODUCING DESULFOVIBRIO IN MURINE MODELS OF ATF6-DRIVEN COLON CANCER

Miriam von Stern-Gwiazdowski

$How to manage refractory reflux$

How to manage refractory reflux

Jordi Serra

TARGETED VERSUS POPULATION-BASED SCREENING AS A PRIMARY PREVENTIVE APPROACH TOWARDS GASTRIC CANCER: INTERIM RESULTS OF THE IRISH EXPERIENCE

Colm O'Morain

UEG Presentation

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

$How to manage refractory reflux$

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

How to manage refractory reflux

Jordi Serra 1

Affiliations

1 University Hospital Vall d'Hebron, Barcelona, Spain

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

Abstract

Event

UEG Week Berlin 2025

Topics

Oesophagus Primary Care Surgery

Session

Managing reflux at multiple levels

Citation

United European Gastroenterology Journal 2025; 13 (Supplement 8)

Published

2025

More Like This:

What treatment can we offer?

Jordi Serra

What the gastroenterologist can offer

Giovanni Sarnelli

DUPILUMAB IMPROVES HISTOPATHOLOGIC DISEASE ACTIVITY OVER 52 WEEKS IN CHILDREN WITH EOSINOPHILIC ESOPHAGITIS: FINDINGS FROM THE PHASE 3 EOE KIDS STUDY

Amr Radwan

WESTERNIZED DIETS EXACERBATE TUMORIGENESIS BY EXPANDING H2S-PRODUCING DESULFOVIBRIO IN MURINE MODELS OF ATF6-DRIVEN COLON CANCER

Miriam von Stern-Gwiazdowski

$How to manage refractory reflux$

How to manage refractory reflux

Jordi Serra

TARGETED VERSUS POPULATION-BASED SCREENING AS A PRIMARY PREVENTIVE APPROACH TOWARDS GASTRIC CANCER: INTERIM RESULTS OF THE IRISH EXPERIENCE

Colm O'Morain

UEG Presentation

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

TARGETED VERSUS POPULATION-BASED SCREENING AS A PRIMARY PREVENTIVE APPROACH TOWARDS GASTRIC CANCER: INTERIM RESULTS OF THE IRISH EXPERIENCE

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Not sure what you can access? Learn more about account types.

TARGETED VERSUS POPULATION-BASED SCREENING AS A PRIMARY PREVENTIVE APPROACH TOWARDS GASTRIC CANCER: INTERIM RESULTS OF THE IRISH EXPERIENCE

Charlene Deane 1, Ana McKiernan 2, Donal Bailey 3, Colm Ó Sé 3, Dean Murray 4, Fiona O'Connor 3, Tom Branigan 5, Anthony Corcoran 5, Marcis Leja 6, Tatjana kofol 7, Bojan Tepes 8, Orlaith Kelly 9, Colm O'Morain 10

Affiliations

1 Connolly Hospital, Dublin, Ireland|||Beacon Hospital Research Institute, Dublin, Ireland

2 Beacon Hospital Research Institute, Dublin, Ireland

3 Irish College of General Practitioners, Dublin, Ireland

4 Royal College of Surgeons Ireland, Dublin, Ireland|||Irish College of General Practitioners, Dublin, Ireland

5 Royal College of Physicians, Ireland, Dublin, Ireland|||Irish Defence Force, Dublin, Ireland

6 University of Latvia, Riga, Latvia

7 National Institute of Public Health, Ljubljana, Slovenia

8 DC ROGASKA d.o.o., Rogaska Slatina, Slovenia

9 Royal College of Surgeons Ireland, Dublin, Ireland|||Connolly Hospital, Dublin, Ireland

10 Beacon Hospital Research Institute, Dublin, Ireland|||Trinity College Dublin - Faculty of Health Sciences, Trinity College Dublin; Dublin/IE, Dublin, Ireland

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

Abstract

Introduction

The TOGAS consortium (TOwards GAstric cancer Screening) was established to explore effective gastric cancer screening strategies within Europe. One key method involves the detection and eradication of Helicobacter pylori (H. pylori), the leading causative agent of gastric cancer. In Western Europe, infection rates are higher among males, smokers, and individuals of lower socioeconomic status—groups that tend to engage less with preventive health services.

Aims & Methods

This pilot study aimed to determine whether targeted screening in high-risk occupational settings improves participation and outcomes compared to population-based screening via general practice.
Key outcome measures included;

Response rate
Prevalence of the infection
Treatment effectiveness

This prospective pilot study recruited individuals aged 30–34 years from January 2024 to March 2025. Participants were invited either through general practices (general population group, GP) or through two occupational screening programs (targeted group, TG) representing higher-risk, male-dominated workforces: the Irish Defence Forces and Construction Workers Health Trust. Exclusion criteria included prior H. pylori treatment or gastrectomy. All participants underwent serologic screening (BIOHIT H. pylori IgG antibody). The TG was offered initial on-site screening at their workplace; the GP group attended a local hospital. All seropositive individuals were offered confirmatory 13-C urea breath testing (Richen IR Force 200) in a local hospital. Confirmed cases were offered a 10-day regimen of PYLERA (Metronidazole/Tetracycline/Bismuth subcitrate) with Esomeprazole 40 mg BD. Eradication was assessed ≥6 weeks post-treatment. Response rates, demographics, infection prevalence, and treatment outcomes were analyzed using Mann-Whitney U and Chi² tests (significance p < 0.05).

Results

3030 individuals were invited for screening: 2824 in the GP group(GPG), 206 in the TG. Key demographics and risk factors of each group are shown in Table 1. The invitation response and participation rates were significantly higher in the TG versus the GPG (31% v’s 14%; p < 0.001, 30% v’s 14% p <0.00, respectively). H. pylori seroprevalence rates were similar between groups: 18% (11/60) in the TG, 19% (64/333) in the GPG (p<0.70). Confirmatory 13-C UBT was completed in 91% (10/11) of those who tested positive in the TG and 98% (63/64) of the GPG. Overall, ‘true’ prevalence rates based on serology & confirmatory 13-C UBT results were 10%(6/59) in the TG v’s 14% (44/325) in the GPG(p = 0.47). Treatment adherence exceeded 90% in both groups, with 100% adherence in the TG and 90% in the GPG. Among those who completed post-treatment testing (n=37), eradication was achieved in 100% of the TG (2/2) and 89% of the GPG (31/35).

Table 1 Basic Demographics by Group

	Targeted group	General population
Gender, male	97%	33%
Median age, years	31	32
Smoking status Current/previous Non-smoker	41% (24) 59% (34)	34% (137) 66% (266)
Socioeconomic status(self-rated) Higher Middle Lower Prefer not to answer	69% (40/58) 22% (13/58) 0 9% (5/58)	85% (337/397) 11% (42/397) 0% (2/397) 4% (16/397)
Family history of H.pylori infection	3% (2)	9% (36)

Conclusion

Targeted occupational screening in high-risk populations demonstrated superior response and engagement rates compared to general practice-based screening. These early results suggest this approach may be a more effective and resource-conscious strategy in low-to-intermediate risk countries and merit further evaluation in broader implementation efforts.

References

1. Teo CH, Ng CJ, Booth A, White A. Barriers and facilitators to health screening in men: A systematic review. Soc Sci Med. 2016 Sep;165:168-176. doi: 10.1016/j.socscimed.2016.07.023. Epub 2016 Aug 1. PMID: 27511617. 5.
2. Lou L, Wang L, Zhang Y, et al. Sex difference in incidence of gastric cancer: an international comparative study based on the Global Burden of Disease Study 2017.BMJ Open 2020;10:e033323. doi: 10.1136/bmjopen-2019-033323
3. Salmani H, Ahmadi M, Shahrokhi N. The Impact of Mobile Health on Cancer Screening: A Systematic Review. Cancer Informatics. 2020;19. doi:10.1177/1176935120954191
4. CSO. (2023, May 30). Employment, Occupation, Industry and Commuting - CSO -Central Statistics Office. https://www.cso.ie/en/releasesandpublications/ep/pcpsr/censusofpopulation2022- summaryresults/employmentoccupationindustryandcommuting/

Disclosure

Dr. Deane reports receipt of research funding support from EU4 Health grant GA number: 101101252. Receipt of 13-C Urea Breath Test bags for this study was provided for by Richen - Dr Deane was the winner of the Richen Global Research Competition 2023

Event

UEG Week Berlin 2025

Topics

Digestive Oncology Endoscopy Stomach & H. Pylori

Submission format

Abstract

Session

Targeting gastric cancer: How to proceed

Citation

United European Gastroenterology Journal 2025; 13 (Supplement 8)

Published

2025

More Like This:

What treatment can we offer?

Jordi Serra

What the gastroenterologist can offer

Giovanni Sarnelli

DUPILUMAB IMPROVES HISTOPATHOLOGIC DISEASE ACTIVITY OVER 52 WEEKS IN CHILDREN WITH EOSINOPHILIC ESOPHAGITIS: FINDINGS FROM THE PHASE 3 EOE KIDS STUDY

Amr Radwan

WESTERNIZED DIETS EXACERBATE TUMORIGENESIS BY EXPANDING H2S-PRODUCING DESULFOVIBRIO IN MURINE MODELS OF ATF6-DRIVEN COLON CANCER

Miriam von Stern-Gwiazdowski

$How to manage refractory reflux$

How to manage refractory reflux

Jordi Serra

TARGETED VERSUS POPULATION-BASED SCREENING AS A PRIMARY PREVENTIVE APPROACH TOWARDS GASTRIC CANCER: INTERIM RESULTS OF THE IRISH EXPERIENCE

Colm O'Morain